stockportfolio.pro
SELLAS Life Sciences Group, Inc. (SLS)
Healthcare · Biotechnology · NasdaqCM
SELLAS Life Sciences Group, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.90M | $7.60M | $1.00M | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | $7.40M | $900,000 | — | — | — |
| Net income | $-17.68M | $-23.75M | $-27.67M | $-19.29M | $-16.76M | $-20.70M | $-41.30M | $-37.34M | $-30.88M | $-26.86M |
| Net margin | — | — | — | — | -881.9% | -272.4% | -4130.1% | — | — | — |
Source: SELLAS Life Sciences Group, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of SELLAS Life Sciences Group, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SLS in your portfolio →
SELLAS Life Sciences Group, Inc. financial history by metric
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
SELLAS Life Sciences Group, Inc. — frequently asked questions
What is SELLAS Life Sciences Group, Inc.'s revenue?
SELLAS Life Sciences Group, Inc. (SLS) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is SELLAS Life Sciences Group, Inc. profitable?
No — SLS reported a net loss of $-26.86M in fiscal 2025.
What is SLS's P/E ratio?
SELLAS Life Sciences Group, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does SELLAS Life Sciences Group, Inc. have?
As of fiscal year 2025, SLS carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is SELLAS Life Sciences Group, Inc.'s market cap?
SELLAS Life Sciences Group, Inc. (SLS) has a market capitalization of about $1.50B, based on the latest data in our nightly-refreshed cache.
When does SELLAS Life Sciences Group, Inc.'s fiscal year end?
SLS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from SELLAS Life Sciences Group, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.